$SENS

TD Cowen reiterated a Buy rating on Senseonics Holdings with a $15 price target, implying a 100.5% upside. The company is testing a next-gen CGM platform, aiming to reduce transmitter dependency, and plans to launch new products, potentially expanding its market share.

Senseonics Holdings has started the first human trial for its Freedom CGM system, which transmits data directly to mobile devices without an external transmitter. The trial focuses on safety and functionality, with plans for a pivotal trial in 2027 and potential commercial release in 2028. The device builds on the Eversense 365 system, aiming to eliminate external components. Preclinical assessments were completed in Q2 2026.

Beta Bionics (BBNX) rose 6.8% to $25.53 after partnering with Senseonics to integrate its insulin delivery systems with Senseonics' Eversence 365 sensor. The first product is expected in Q4. CEO Sean Saint highlighted the expanded reach for diabetes management.

TD Cowen reiterated a Buy rating and $15.00 price target for Senseonics Holdings (SENS), citing growth drivers like U.S. direct-to-consumer conversions and Europe rebound. The stock is up 73% YTD. Q2 2026 revenue surged 120% YoY to $14.5M, beating estimates, but loss per share widened slightly. Gross margin is 55%, with analysts expecting continued sales growth.

Beta Bionics (BBNX) received FDA clearance for its Mint patch pump, aiming for a Q1 2027 U.S. launch. The company also unveiled 3D Intelligence, a next-gen insulin dosing algorithm. Beta Bionics lowered its 2026 revenue outlook to $121M-$126M, citing potential revenue deferral. A partnership with Senseonics (SENS) was announced for integrating Eversense 365 with iLet Bionic Pancreas.

ROEDER DOUGLAS A purchased 13,953 shares of Senseonics Holdings, Inc. (SENS) at $8.98 ($0.13M total) on 2026-08-19.

On CNBC’s “Mad Money Lightning Round,” Jim Cramer recommended buying Carpenter Technology (CRS) after it announced a $1 billion buyback and a 20 cents per share quarterly dividend. He called DXC Technology (DXC) a “value trap” after mixed Q2 results. He also commented on several other stocks including SENS, Ubiquiti (UI), Hess Midstream (HESM), Zeta Global, UL Solutions, and Coupang.

Senseonics Holdings, Inc. (SENS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results ● Generated second quarter revenue of $14.5 million, an increase of approximately 120% year-over-year ● Raising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million,

Senseonics Holdings, Inc., a medical technology company focused on continuous glucose monitoring (CGM) systems, announced the successful closing of its $92 million public offering. The offering included common stock and pre-funded warrants, with the underwriters fully exercising their option to purchase additional shares. This capital raise will support the company's ongoing development and commercialization efforts for its implantable CGM devices.

Senseonics Holdings, Inc. announced the commencement of an underwritten public offering of its common stock and pre-funded warrants, aiming to raise $80 million. The company plans to use the net proceeds to fund the launch of Eversense 365, continue developing pipeline products, and for general corporate purposes. TD Cowen and Barclays are acting as joint book-running managers for the offering.